144 related articles for article (PubMed ID: 15899799)
1. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
2. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
3. EPCA-2: a highly specific serum marker for prostate cancer.
Leman ES; Cannon GW; Trock BJ; Sokoll LJ; Chan DW; Mangold L; Partin AW; Getzenberg RH
Urology; 2007 Apr; 69(4):714-20. PubMed ID: 17445657
[TBL] [Abstract][Full Text] [Related]
4. Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia.
Zhao Z; Zeng G
Endocr Relat Cancer; 2010 Jun; 17(2):505-12. PubMed ID: 20308359
[TBL] [Abstract][Full Text] [Related]
5. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
6. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
[TBL] [Abstract][Full Text] [Related]
7. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer.
Walgenbach-Brunagel G; Burger B; Leman ES; Walgenbach KJ; Tolba R; Heukamp L; Hirner A; Getzenberg RH
J Cell Biochem; 2008 May; 104(1):286-94. PubMed ID: 18044711
[TBL] [Abstract][Full Text] [Related]
8. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new serum testing method for detection of prostate cancer.
Seabury CA; Calenoff E; Ditlow C; Bux S; Clarke H; Issa M; Marshall F; Petros J
J Urol; 2002 Jul; 168(1):93-9. PubMed ID: 12050499
[TBL] [Abstract][Full Text] [Related]
10. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
[TBL] [Abstract][Full Text] [Related]
11. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
[TBL] [Abstract][Full Text] [Related]
12. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers.
Miller JC; Zhou H; Kwekel J; Cavallo R; Burke J; Butler EB; Teh BS; Haab BB
Proteomics; 2003 Jan; 3(1):56-63. PubMed ID: 12548634
[TBL] [Abstract][Full Text] [Related]
13. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
14. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
Schostak M; Schwall GP; Poznanović S; Groebe K; Müller M; Messinger D; Miller K; Krause H; Pelzer A; Horninger W; Klocker H; Hennenlotter J; Feyerabend S; Stenzl A; Schrattenholz A
J Urol; 2009 Jan; 181(1):343-53. PubMed ID: 19012935
[TBL] [Abstract][Full Text] [Related]
15. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H
J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
[TBL] [Abstract][Full Text] [Related]
18. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
Bradford TJ; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]